SCHEMBL200521

SCHEMBL200521

CCc1cccc(C(=O)O)c1CBr

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLCN2 P51788 1/20 0.50
HMGB1 P09429 1/20 0.42
GABRA1 P14867 2/20 0.42
GABRB2 P47870 2/20 0.42
FOLH1 Q04609 2/20 0.42
ALDH1A1 P00352 4/20 0.41
ALOX15 P16050 2/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 2/20 0.40
HTT P42858 3/20 0.39
TSHR P16473 3/20 0.39
CYP2C19 P33261 1/20 0.38
HIF1A Q16665 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NR4A1 P22736 1/20 0.37
NR4A2 P43354 1/20 0.37
NR4A3 Q92570 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7944652 0.89 CLCN2 (0.50) CLCN2HMGB1GABRA1GABRB2FOLH1
SCHEMBL8885426 0.89 ALDH1A1 (0.44) CLCN2HMGB1FOLH1ALDH1A1ALOX15
SCHEMBL578127 0.88 CLCN2 (0.56) CLCN2HMGB1GABRA1GABRB2FOLH1
Ammonia Solution, Strong SCHEMBL29557133 0.86 CLCN2 (0.54) CLCN2HMGB1GABRA1GABRB2FOLH1
SCHEMBL27437637 0.85 HMGB1 (0.42) CLCN2HMGB1FOLH1ALDH1A1ALOX15
SCHEMBL27338933 0.84 ALDH1A1 (0.52) HMGB1FOLH1ALDH1A1ALOX15KDM4E
SCHEMBL3420974 0.84 PARP1 (0.44) CLCN2GABRA1GABRB2ALDH1A1KDM4E
SCHEMBL7477512 0.81 CLCN2 (0.50) CLCN2HMGB1GABRA1GABRB2FOLH1
SCHEMBL4973094 0.81 GABRP (0.39) CLCN2GABRA1GABRB2ALDH1A1ALOX15
SCHEMBL15344588 0.81 CLCN2 (0.50) CLCN2HMGB1GABRA1GABRB2FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088926-B2 Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity JENRIN DISCOVERY, INC. (US) 2012-01-03 US disclosed
US-6787556-B1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR) AGONISTS; type 2 gamma receptors; INSULIN RESISTANCE; carboxybenzyl group on a phenyl-substituted tetrazole, pyrazole, or imidazole ring ASTRAZENECA AB (SE) 2004-09-07 US disclosed
EP-1210339-A1 BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS AstraZeneca AB (SE) 2002-06-05 EP disclosed
EP-1161411-A2 BENZYLIC HALOGENATION OF ALKYLBENZOIC ACID ESTERS ALBEMARLE CORPORATION (US) 2001-12-12 EP disclosed
WO-2001012612-A1 BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS ASTRAZENECA AB (SE) 2001-02-22 WO disclosed
WO-2000053564-A2 BENZYLIC HALOGENATION OF ALKYLBENZOIC ACID ESTERS ALBEMARLE CORPORATION (US) 2000-09-14 WO disclosed
WO-2000002903-A1 CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME CYTEL CORPORATION (US) 2000-01-20 WO disclosed
US-4555516-A FOR TREATMENT OF CARDIOVASCULAR DISORDERS PFIZER INC. (US) 1985-11-26 US disclosed